Article Text

Download PDFPDF
Review: antipsychotic augmentation is effective for people with obsessive-convulsive disorder who are receiving, but not responding to, serotonin reuptake inhibitor monotherapy

Statistics from

OpenUrlCrossRefPubMedWeb of Science

Q Does augmentation with antipsychotics improve outcome for people with refractory obsessive-compulsive disorder who are not responding to serotonin reuptake inhibitor monotherapy?


Embedded ImageDesign:

Systematic review with meta-analysis.

Embedded ImageData sources:

PubMed and PsychINFO (1967–2005), EMBASE (1974–2000) and the Cochrane Central Register of Controlled Trials (Issue 3, 2005). Reference lists were hand searched.

Embedded ImageStudy selection and analysis:

Eligible studies were double blinded, randomised controlled trials (RCTs) that compared augmentation with antipsychotic versus placebo in adults with obsessive-compulsive disorder that had not responded to ⩾2 months serotonin reuptake inhibitor (SRI) monotherapy, and that used the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) as an outcome measure. Pooled absolute risk difference (RD) was used to analyse proportion of treatment responders and number needed to treat …

View Full Text


  • For correspondence: Dr M H Bloch, Child Study Center, Yale University School of Medicine, 230 South Frontage Road, New Haven, CT 06520, USA; michael.bloch{at}

  • Sources of funding: not stated.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.